Metastatic HER2 Positive Gastroesophageal Junction Cancer
4 clinical trials · Condition
◉ Watch Metastatic HER2 Positive Gastroesophageal Junction Cancer
| Record | Firm | Date |
|---|---|---|
| Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients (NCT06650332) | Zhejiang Cancer Hospital | 2024-07-10 |
| CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma (NCT05207722) | Celularity Incorporated | 2022-04-14 |
| A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. (NCT05141747) | Shanghai Miracogen Inc. | 2022-01-19 |
| TAC T-cells for the Treatment of HER2-positive Solid Tumors (NCT04727151) | Triumvira Immunologics, Inc. | 2021-04-19 |
Track Metastatic HER2 Positive Gastroesophageal Junction Cancer automatically
Every clearance here is in the API, with alerts when new ones post.